Futurology: Are Mega Mergers A Thing Of The Past?
Executive Summary
Bolt-ons or big-ticket buys? As another year passes without a big pharma mega merger despite industry giants sitting on large cash piles, we consider whether 2018 will bring major upheaval in the industry landscape, and where M&A will be most likely to take place.
You may also be interested in...
Biden Infrastructure Plan Offers Biopharma R&D Carrot, Tax Stick
Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.
Tax Reform Provides Environment For M&A Surge, EY Report Says
2018 should see an increase in significant biopharma deal-making, possibly even a mega-merger, as US companies are able to repatriate offshore cash at lower tax rates.
Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.